Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials

Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron

(2011) David H. Henry et al.   AMERICAN JOURNAL OF HEMATOLOGY

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials

(2011) Fausto Petrelli et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Too-Low Iron Doses and Too Many Dropouts in Negative Iron Trial?

(2011) Matti Aapro et al.   JOURNAL OF CLINICAL ONCOLOGY

Subgroups of Advanced Cancer Patients Clustered by Their Symptom Profiles: Quality-of-Life Outcomes

(2011) Amna Husain et al.   JOURNAL OF PALLIATIVE MEDICINE

Parenteral Iron Therapy in Cancer-Associated Anemia

(2011) D. H. Henry   Hematology-American Society of Hematology Education Program

Erythropoiesis-stimulating agents in cancer patients: reflections on safety

(2011) Isabelle Wauters et al.   Expert Review of Clinical Pharmacology

Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous Iron in patients with chemotherapy-induced anemia

(2010) Michael Auerbach et al.   AMERICAN JOURNAL OF HEMATOLOGY

Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use

(2010) D. Schrijvers et al.   ANNALS OF ONCOLOGY

Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy

(2010) Penkae Dangsuwan et al.   GYNECOLOGIC ONCOLOGY

American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer

(2010) J. Douglas Rizzo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated Anemia

(2010) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia

(2009) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

(2009) Julia Bohlius et al.   LANCET

Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: Systematic Review and Meta-analysis

(2008) Benaya Rozen-Zvi et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia

(2008) Charles L. Bennett   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2008) Robert E. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia

(2008) Laurent Bastit et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

(2008) Paolo Pedrazzoli et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of iron supplementation during epoietin treatment for cancer-related anemia

(2008) M. Hedenus et al.   MEDICAL ONCOLOGY